about
Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort studySuvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled TrialsBridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceMedication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.Fatal crashes from drivers testing positive for drugs in the U.S., 1993-2010.Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA)Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey.Adverse performance effects of acute lorazepam administration in elderly long-term users: pharmacokinetic and clinical predictors.Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study.Substance-related traffic-risk behaviors among college students.Reimbursement restriction and moderate decrease in benzodiazepine use in general practice.Behavioral and Neurophysiological Signatures of Benzodiazepine-Related Driving ImpairmentsPrevalence of alcohol and drug use in injured British Columbia drivers.American Geriatrics Society identifies five things that healthcare providers and patients should question.Drugs and alcohol: their relative crash risk.Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010.Long-term sedative use among community-dwelling adults: a population-based analysis.Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence.Benzodiazepines, opioids and driving: an overview of the experimental research.Meta-analysis of on-the-road experimental studies of hypnotics: effects of time after intake, dose, and half-life.The reappraisal of benzodiazepines in the treatment of anxiety and related disorders.Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research.Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.Beliefs about the consequences of using benzodiazepines among persons with opioid use disorder.Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards.Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs.European guideline for the diagnosis and treatment of insomnia.Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series study in Australia.Different aspects of driving under the influence of benzodiazepines.Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.
P2860
Q21260318-50ECF9AD-CFFB-4A24-8FD0-F78BBAC6050BQ26796379-2DD94935-9AC2-44B7-B4CD-56E39872B5D8Q26800235-73ED4867-07F2-4BBE-97E1-3173A21BE765Q30248258-442A8806-FC6F-4C2D-B87D-8E901B9F504FQ33681104-375C3F1A-F3E5-48B4-BE74-F5EDB80EE6DFQ34580631-2BAC7269-8A5B-4E37-87AD-558626EEF962Q34623459-855E2169-676C-4B6A-9DEE-011580B1EE21Q34646697-65AA1A82-BD0A-4693-9E15-EBAAE4B7FB4CQ34646729-BF8FCD48-9EE2-4F2A-8F87-A63AF8FAAFC6Q35179458-D4691A5D-6CA7-4C7A-BF4F-AB82AAF7F7B0Q35684159-745CCC2C-64AD-4EA3-BE62-97DC9814263BQ36320094-5A996941-360B-49F5-8699-CCE01434F35BQ36707458-0CB71E55-1FA9-4045-A47B-85A86937A969Q37205382-61BC3EEE-D3EC-4CB5-AEB4-5BF1DEF4F5A9Q37485972-8E0D6B3E-97D5-4854-8E4F-F88E0305EBEBQ37612582-DDC78BC5-6EA4-40D9-B69F-2469DFC45B47Q37735891-5EDCC64A-E937-455D-8EED-58B66E80DAE7Q37830027-051DF7CF-E628-400A-A6A8-944CF5840071Q37872349-F7E1F765-6B7B-4B29-BD74-7AE161957C6BQ38200102-74F3B99D-6AB4-4638-89F3-BCC0A087D7E4Q38252986-DD124CA4-5616-416D-BD52-165794979BCBQ38634049-B572E665-329D-4326-BE00-6962AEA4FA40Q38869554-5E79196A-DADC-4C22-9B4F-9FE1332DA997Q44345419-1D960CFE-CAC1-46C6-9B68-19DE5DAB6665Q44349070-C476B258-C909-4191-8418-6F48A5122EF9Q44945015-9570AF56-C320-429A-86D2-3035C85266FDQ47628865-D1626C42-9D79-4405-8BE4-AB942167B02BQ48732635-7D0BAF3B-3D35-4592-B18D-01D116A11243Q53743792-6A3F9D2C-5E48-40FC-8072-DD2A40F38E80Q54636663-1A7ECFA6-5D7B-4CA8-9531-1674C71511DB
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Benzodiazepine Use and Driving
@ast
Benzodiazepine Use and Driving
@en
Benzodiazepine Use and Driving
@en-gb
Benzodiazepine Use and Driving
@nl
type
label
Benzodiazepine Use and Driving
@ast
Benzodiazepine Use and Driving
@en
Benzodiazepine Use and Driving
@en-gb
Benzodiazepine Use and Driving
@nl
altLabel
Benzodiazepine use and driving: a meta-analysis
@en
prefLabel
Benzodiazepine Use and Driving
@ast
Benzodiazepine Use and Driving
@en
Benzodiazepine Use and Driving
@en-gb
Benzodiazepine Use and Driving
@nl
P2093
P50
P356
P1476
Benzodiazepine use and driving: a meta-analysis
@en
P2093
Ayal Schaffer
Evelyn Vingilis
Kenneth I Shulman
Mark J Rapoport
Michel Bédard
Nathan Herrmann
P304
P356
10.4088/JCP.08M04325
P407
P577
2009-04-21T00:00:00Z